Brief: Neoleukin Therapeutics Reports Qtrly Net Loss Per Share $0.28
09/08/2022 22:09
Aug 9 (Reuters) - Neoleukin Therapeutics Inc NLTX.O :
* NEOLEUKIN THERAPEUTICS ANNOUNCES SECOND QUARTER 2022
FINANCIAL
RESULTS & PROVIDES CORPORATE UPDATE
* QTRLY NET LOSS PER SHARE $0.28
* NEOLEUKIN THERAPEUTICS - BASED UPON CURRENT INTERNAL
INFRASTRUCTURE AND PIPELINE INITIATIVES, BELIEVE CO HAS
SUFFICIENT CASH TO FUND OPERATIONS THROUGH 2023
* Q2 EARNINGS PER SHARE VIEW $-0.30 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNXc6Kv7Y
Further company coverage: NLTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurogene
See all newsBrief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Neurogene Inc reports results for the quarter ended June 30 - Earnings Summary
Neurogene Q2 adjusted loss per share misses estimates on employee costs
Neurogene Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Kroger, Meta, Sable